Abstract
Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein.
Stephanie O Keeling, Robert Landewe, Desiree van der Heijde, Joan Bathon, Maarten Boers, Patrick Garnero, Piet Geusens, Hani El-Gabalawy, Robert D Inman, Virginia B Kraus, Tore K Kvien, Philip J Mease, Mikkel Ostergaard, Chris Ritchlin, Silje W Syversen and Walter P Maksymowych
The Journal of Rheumatology March 2007, 34 (3) 623-633;
Stephanie O Keeling
Robert Landewe
Desiree van der Heijde
Joan Bathon
Maarten Boers
Patrick Garnero
Piet Geusens
Hani El-Gabalawy
Robert D Inman
Virginia B Kraus
Tore K Kvien
Philip J Mease
Mikkel Ostergaard
Chris Ritchlin
Silje W Syversen
In this issue
The Journal of Rheumatology
Vol. 34, Issue 3
1 Mar 2007
Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein.
Stephanie O Keeling, Robert Landewe, Desiree van der Heijde, Joan Bathon, Maarten Boers, Patrick Garnero, Piet Geusens, Hani El-Gabalawy, Robert D Inman, Virginia B Kraus, Tore K Kvien, Philip J Mease, Mikkel Ostergaard, Chris Ritchlin, Silje W Syversen, Walter P Maksymowych
The Journal of Rheumatology Mar 2007, 34 (3) 623-633;
Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein.
Stephanie O Keeling, Robert Landewe, Desiree van der Heijde, Joan Bathon, Maarten Boers, Patrick Garnero, Piet Geusens, Hani El-Gabalawy, Robert D Inman, Virginia B Kraus, Tore K Kvien, Philip J Mease, Mikkel Ostergaard, Chris Ritchlin, Silje W Syversen, Walter P Maksymowych
The Journal of Rheumatology Mar 2007, 34 (3) 623-633;